These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24115268)

  • 1. MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases.
    Flatley B; Wilmott KG; Malone P; Cramer R
    Prostate; 2014 Jan; 74(1):103-11. PubMed ID: 24115268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions.
    Okamoto A; Yamamoto H; Imai A; Hatakeyama S; Iwabuchi I; Yoneyama T; Hashimoto Y; Koie T; Kamimura N; Mori K; Yamaya K; Ohyama C
    Oncol Rep; 2009 Jan; 21(1):73-9. PubMed ID: 19082445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles.
    Calvano CD; Aresta A; Iacovone M; De Benedetto GE; Zambonin CG; Battaglia M; Ditonno P; Rutigliano M; Bettocchi C
    J Pharm Biomed Anal; 2010 Mar; 51(4):907-14. PubMed ID: 19939598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer biomarker discovery using high performance mass spectral serum profiling.
    Oh JH; Lotan Y; Gurnani P; Rosenblatt KP; Gao J
    Comput Methods Programs Biomed; 2009 Oct; 96(1):33-41. PubMed ID: 19423179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.
    Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A
    Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadriplex model enhances urine-based detection of prostate cancer.
    Jamaspishvili T; Kral M; Khomeriki I; Vyhnankova V; Mgebrishvili G; Student V; Kolar Z; Bouchal J
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):354-60. PubMed ID: 21788966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.
    Nakayama K; Inoue T; Sekiya S; Terada N; Miyazaki Y; Goto T; Kajihara S; Kawabata S; Iwamoto S; Ikawa K; Oosaga J; Tsuji H; Tanaka K; Ogawa O
    PLoS One; 2014; 9(9):e107234. PubMed ID: 25233230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry.
    Callesen AK; Christensen Rd; Madsen JS; Vach W; Zapico E; Cold S; Jørgensen PE; Mogensen O; Kruse TA; Jensen ON
    Rapid Commun Mass Spectrom; 2008; 22(3):291-300. PubMed ID: 18181248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
    Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
    Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine.
    M'Koma AE; Blum DL; Norris JL; Koyama T; Billheimer D; Motley S; Ghiassi M; Ferdowsi N; Bhowmick I; Chang SS; Fowke JH; Caprioli RM; Bhowmick NA
    Biochem Biophys Res Commun; 2007 Feb; 353(3):829-34. PubMed ID: 17194448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification.
    Fania C; Sogno I; Vasso M; Torretta E; Leone R; Bruno A; Consonni P; Albini A; Gelfi C
    Clin Chim Acta; 2015 Jan; 439():42-9. PubMed ID: 25312866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary prostate-specific antigen and microseminoprotein-beta levels in men with and without prostate cancer: A prospective cohort study.
    Shrivastava P; Garg H; Bhat M; Dinda A; Kumar R
    Indian J Urol; 2020; 36(1):50-55. PubMed ID: 31983827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
    Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
    J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
    Brikun I; Nusskern D; Decatus A; Harvey E; Li L; Freije D
    Clin Epigenetics; 2018; 10():91. PubMed ID: 29988684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer.
    Pallua JD; Schaefer G; Seifarth C; Becker M; Meding S; Rauser S; Walch A; Handler M; Netzer M; Popovscaia M; Osl M; Baumgartner C; Lindner H; Kremser L; Sarg B; Bartsch G; Huck CW; Bonn GK; Klocker H
    J Proteomics; 2013 Oct; 91():500-14. PubMed ID: 23954705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
    Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry].
    Pan YZ; Xiao XY; Zhao D; Zhang L; Ji GY; Li Y; He DC; Zhao XJ; Yang BX
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3172-5. PubMed ID: 16405834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection.
    Rogers CG; Gonzalgo ML; Yan G; Bastian PJ; Chan DY; Nelson WG; Pavlovich CP
    J Urol; 2006 Nov; 176(5):2280-4. PubMed ID: 17070312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of blood sampling on protein profiling and pattern analysis using matrix-assisted laser desorption/ionisation mass spectrometry.
    Pelzer AE; Feuerstein I; Fuchsberger C; Ongarello S; Bektic J; Schwentner C; Klocker H; Bartsch G; Bonn GK
    BJU Int; 2007 Mar; 99(3):658-62. PubMed ID: 17407520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.